What is already known about this subject
- Phase III trials for regulatory approval typically have conducted
under strict eligibility criteria that exclude certain patients.
- These ineligible patients often receive the approved drugs post-trial.
- The balance of risks and benefits for these ineligible patients
remains unclear.